GlassScriptPhysician profile
Margo Bolander
NPI 1386091361
$8,025.59
in general payments reported to CMS, 2019-2025
49 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,379 · 2022: $2,940 · 2023: $1,858 · 2024: $1,602 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109 · Long Term Medical Supply Or Device Loan: $299 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,109.32 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $297.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $876.14 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $649.74 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Pfizer INC. | $601.96 | 2021-2025 | |
| Amgen INC. | $566.17 | 2021-2023 | Kyprolis, Lumakras |
| Janssen Biotech, INC. | $449.06 | 2021-2025 | Darzalex, Erleada, Imbruvica |
| Astellas Pharma US INC | $383.18 | 2021-2024 | Xtandi |
| Genentech USA, INC. | $365.42 | 2021-2023 | Venclexta, Phesgo, Polivy |
| Lilly USA, LLC | $360.91 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $334.03 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $326.23 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $285.77 | 2021-2023 | Adcetris |
| Celgene Corporation | $270.14 | 2021-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $251.90 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $226.08 | 2021-2024 | Opdivo, Opdualag |
| Beigene USA, INC. | $209.16 | 2022-2025 | Brukinsa |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Bolander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.